Saturday, October 3, 2026
ExploreSearch
Via News
MarketFX

USD/CNH Went Down By Over 1% In The Last 10 Sessions

USD/CNH Went Down By Over 1% In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.72% for the last 10 sessions. At 13:08 EST on Sunday, 3 March, USD/CNH (USDCNH) is $7.20.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0% down from its 52-week high.

News about

  • Eur/usd tests strength of 1.0800 as eurozone’s inflation remains stickier than consensus. According to FXStreet on Friday, 1 March, "The EUR/USD pair walks on thin ice near the crucial support of 1.0800 in Friday's European session. "
  • According to FXStreet on Friday, 1 March, "All this is translating into a resilient Dollar, with EUR/USD trading at 1.0800, which looks fair to us given market conditions."
  • Eur/usd will struggle to make any sustained move higher over the near term – MUFG. According to FXStreet on Friday, 1 March, "Economists at MUFG Bank do not expect the EUR/USD pair to move sustainably higher over the short term.", "Inflation forecasts for 2025 and 2026 are already around target at 2.1% and 1.9% so that will make it difficult for EUR/USD to make any sustained move higher over the near term."
  • Eur/usd will close the week relatively unchanged around 1.0800 – commerzbank. According to FXStreet on Friday, 1 March, "I can therefore well imagine that EUR/USD will close the week relatively unchanged around 1.0800. "

More news about USD/CNH (USDCNH).

Categories

MarketFX

Tags

ForexForeign Exchange MarketCurrenciesUSDCNHUSD/CNHPrice DownFOREX Price DownForex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com